Add this topic to your myFT Digest for news straight to your inbox
Authorities are investigating whether companies aggravated a shortage of the vital medical product to boost profits
Pfizer will probably come up with another big plan. Too bad
‘We are operating under today’s laws, written by US Congress’ says chief
Pharma has seen a vigorous period of dealmaking
Wider market mixed, with energy sector best performer on back of oil price rise
New kind of copycat drugs pose threat to big pharma
Advisory fees for some transactions will land later in the year
How AbbVie came out on top in pharma’s most competitive auction
Johnson & Johnson explores acquisition of US cancer drugs maker
Cut-price versions of blockbuster anti-inflammatory drugs go on sale
Deal marks return to big-ticket M&A after the defeat of Allergan bid last year
Rising profits blunt concerns that the sector is overvalued
Slew of deals announced this week a healthy sign
No AstraZeneca, no problem for the US group
Purchase of injectables and biosimilars specialist will pave way for standalone units
Independent investment banks win market share from Wall St rivals
Healthcare group’s strong position in biosimilars makes it very appealing
US group to snap up provider of injectable drugs and biosimilars
Talks come against a challenging backdrop for French yoghurt group
Tiffany shares hit by US and European weakness
International Edition